# 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets

> **NCT02735798** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Pamela Munster**

## Conditions studied

- Brain Metastases
- Documented Her2 Overexpression
- Advanced Solid Tumor
- Neurologically Stable

## Interventions

- **DRUG:** MM-302
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02735798
- **Lead sponsor:** Pamela Munster
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-04
- **Primary completion:** 2017-06
- **Final completion:** 2018-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was not started due to the sponsor choosing to not fund the trial.
- **Last updated:** 2017-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02735798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02735798, "64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02735798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*